Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

NCT02792231 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

955

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Multiple Scelrosis

Interventions

DRUG: Ofatumumab subcutaneous injection
DRUG: Teriflunomide-matching placebo capsules
DRUG: Teriflunomide capsule
DRUG: Matching placebo of ofatumumab subcutaneous injections

Sponsor

Novartis Pharmaceuticals